ketorolac has been researched along with Adverse Drug Event in 5 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Method We performed a cost-effectiveness analysis of three clinical rules of the CMA, targeting adverse drug events at three levels of severity: A) persistent opioid-induced constipation, B) ketorolac-induced gastrointestinal bleeding and C) drug-induced Torsade de Pointes." | 4.12 | Cost-effectiveness of check of medication appropriateness: methodological approach. ( Bisschops, R; D'hulster, E; Luyten, J; Peetermans, WE; Quintens, C; Verbakel, JY; Willems, R, 2022) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| "Ketorolac is a nonsteroidal antiinflammatory drug widely used as an adjunct to postoperative pain control in adult and pediatric patients." | 1.37 | Safety of ketorolac in surgical neonates and infants 0 to 3 months old. ( Aldrink, JH; Caniano, DA; Ma, M; Puthoff, T; Wang, W; Wispe, J, 2011) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| D'hulster, E | 1 |
| Quintens, C | 1 |
| Bisschops, R | 1 |
| Willems, R | 1 |
| Peetermans, WE | 1 |
| Verbakel, JY | 1 |
| Luyten, J | 1 |
| Aldrink, JH | 1 |
| Ma, M | 1 |
| Wang, W | 1 |
| Caniano, DA | 1 |
| Wispe, J | 1 |
| Puthoff, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Randomized, Allocation-Concealed, Blinded Study Designed to Compare Ketorolac Sublingual and Fentanyl Intranasal in Pain Control for Bilateral Myringotomy and Tubes (BMT) Placement in Children[NCT02653742] | Phase 4 | 150 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
| A Randomized, Double-blinded, Placebo-controlled Study of Ketorolac Use in Pediatric Patients Undergoing Tonsillectomy[NCT03453541] | Phase 4 | 600 participants (Anticipated) | Interventional | 2017-11-21 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 other studies available for ketorolac and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Cost-effectiveness of check of medication appropriateness: methodological approach.
Topics: Analgesics, Opioid; Constipation; Cost-Benefit Analysis; Drug-Related Side Effects and Adverse React | 2022 |
Safety of ketorolac in surgical neonates and infants 0 to 3 months old.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Dose-Response Relationship, Drug; Drug Admi | 2011 |
Safety of ketorolac in surgical neonates and infants 0 to 3 months old.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Dose-Response Relationship, Drug; Drug Admi | 2011 |
Safety of ketorolac in surgical neonates and infants 0 to 3 months old.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Dose-Response Relationship, Drug; Drug Admi | 2011 |
Safety of ketorolac in surgical neonates and infants 0 to 3 months old.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Dose-Response Relationship, Drug; Drug Admi | 2011 |